Integra LifeSciences (NASDAQ:IART) Downgraded by Oppenheimer

Oppenheimer downgraded shares of Integra LifeSciences (NASDAQ:IARTFree Report) from an outperform rating to a market perform rating in a report published on Tuesday morning, Marketbeat Ratings reports.

Several other analysts also recently weighed in on the stock. StockNews.com downgraded shares of Integra LifeSciences from a buy rating to a hold rating in a report on Tuesday, April 30th. Citigroup upgraded shares of Integra LifeSciences from a sell rating to a neutral rating and set a $38.00 target price for the company in a report on Wednesday, April 3rd. Wells Fargo & Company downgraded shares of Integra LifeSciences from an overweight rating to an equal weight rating and dropped their target price for the company from $45.00 to $25.00 in a report on Tuesday. JMP Securities dropped their target price on shares of Integra LifeSciences from $55.00 to $49.00 and set a market outperform rating for the company in a report on Thursday, February 29th. Finally, Truist Financial decreased their price target on shares of Integra LifeSciences from $46.00 to $41.00 and set a hold rating for the company in a research report on Friday, March 1st. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of Hold and a consensus target price of $36.80.

View Our Latest Stock Report on IART

Integra LifeSciences Trading Up 2.7 %

Shares of NASDAQ IART traded up $0.69 during midday trading on Tuesday, reaching $25.99. 1,420,261 shares of the stock were exchanged, compared to its average volume of 1,182,538. The company has a 50 day simple moving average of $32.24 and a 200 day simple moving average of $37.98. The stock has a market capitalization of $2.04 billion, a P/E ratio of 51.98, a PEG ratio of 0.70 and a beta of 1.17. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.18 and a current ratio of 3.45. Integra LifeSciences has a twelve month low of $22.36 and a twelve month high of $50.78.

Integra LifeSciences (NASDAQ:IARTGet Free Report) last posted its earnings results on Monday, May 6th. The life sciences company reported $0.55 earnings per share for the quarter, meeting the consensus estimate of $0.55. Integra LifeSciences had a net margin of 2.63% and a return on equity of 14.23%. The firm had revenue of $368.90 million during the quarter, compared to the consensus estimate of $361.96 million. During the same quarter last year, the firm earned $0.74 EPS. The firm’s revenue for the quarter was down 3.2% on a year-over-year basis. As a group, equities analysts expect that Integra LifeSciences will post 3.17 earnings per share for the current year.

Institutional Investors Weigh In On Integra LifeSciences

Institutional investors have recently modified their holdings of the company. Arizona State Retirement System lifted its position in Integra LifeSciences by 1.3% in the third quarter. Arizona State Retirement System now owns 20,988 shares of the life sciences company’s stock valued at $802,000 after acquiring an additional 279 shares during the last quarter. Cardinal Capital Management lifted its position in Integra LifeSciences by 1.6% in the fourth quarter. Cardinal Capital Management now owns 22,101 shares of the life sciences company’s stock valued at $962,000 after acquiring an additional 347 shares during the last quarter. Hexagon Capital Partners LLC lifted its position in Integra LifeSciences by 123.3% in the fourth quarter. Hexagon Capital Partners LLC now owns 670 shares of the life sciences company’s stock valued at $29,000 after acquiring an additional 370 shares during the last quarter. Inspire Investing LLC lifted its position in Integra LifeSciences by 5.1% in the third quarter. Inspire Investing LLC now owns 8,004 shares of the life sciences company’s stock valued at $306,000 after acquiring an additional 392 shares during the last quarter. Finally, State of Michigan Retirement System lifted its position in Integra LifeSciences by 2.5% in the first quarter. State of Michigan Retirement System now owns 16,690 shares of the life sciences company’s stock valued at $592,000 after acquiring an additional 400 shares during the last quarter. 84.78% of the stock is owned by hedge funds and other institutional investors.

Integra LifeSciences Company Profile

(Get Free Report)

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.

Read More

Analyst Recommendations for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.